Literature DB >> 318916

A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.

F Ansfield, J Klotz, T Nealon, G Ramirez, J Minton, G Hill, W Wilson, H Davis, G Cornell.   

Abstract

A clinical trial involving 462 colon, rectum, and breast cancer patients randomized among four different dosage regimens of 5-FU (an intravenous loading course, a weekly intravenous schedule, a nontoxic schedule, and an oral schedule) has shown a significantly better response among colon-rectum cancer patients for the intravenous loading course. In addition, duration of response and time to progression are also significantly better. Overall survival is approaching significance for the colon rectum group (p value .082). In contrast, breast cancer patients show little difference between treatments. Toxicity is somewhat higher for the loading course.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 318916     DOI： 10.1002/1097-0142(197701)39:1<34::aid-cncr2820390107>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  27 in total

1.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.

Authors:  C J Fabian; R Molina; M Slavik; S Dahlberg; S Giri; R Stephens
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma.

Authors:  M L McMaster; F A Greco; D H Johnson; J D Hainsworth
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro.

Authors:  R Kanamaru; H Kakuta; T Sato; C Ishioka; A Wakui
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).

Authors:  Patricia M LoRusso; Sucharu Prakash; Antoinette Wozniak; Lawrence Flaherty; Mark Zalupski; Anthony Shields; Howard Sands; Ralph Parchment; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

5.  Phase I trial of 5-fluorouracil by 24-hour infusion weekly.

Authors:  N B Haas; J B Hines; G R Hudes; N Johnston; R F Ozols; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

Review 6.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 7.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

8.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

9.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

10.  Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells.

Authors:  P P Major; E M Egan; L Sargent; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.